Kadmon Presents New Preclinical Data on its Immuno-Oncology Fusion Protein at SITC Annual Meeting
November 06, 2018 08:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for...
Kadmon Announces Oral Presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting
November 01, 2018 09:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that updated data from its ongoing Phase 2 clinical trial evaluating KD025 for the treatment of chronic...
Kadmon Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versus-Host Disease
October 25, 2018 08:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the first patient has been dosed in a pivotal clinical trial of KD025 in chronic graft-versus-host...
Kadmon Announces CFO Transition and Other Updates
October 24, 2018 16:15 ET
|
Kadmon Holdings, Inc.
NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Konstantin Poukalov has notified the company of his intent to step down as Executive Vice...
FDA Grants Breakthrough Therapy Designation to Kadmon's KD025 for Chronic Graft-Versus-Host Disease
October 17, 2018 09:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KD025,...
Kadmon to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 29, 2018 09:00 ET
|
Kadmon Holdings, Inc.
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Rodman &...